All Episodes

S6.14.3 - Louise and Roger React to Empowered SLD Patient Advocates

S6.14.2 - Goals of the Stephen A. Harrison Patient Advocacy Fellowship Program

S6.14.1 - How the Harrison Patient Advocacy Fellowship Came To Be

S6.14 - Introducing the Dr. Stephen A. Harrison Patient Advocacy Fellowship Program

S6.13.3 - Major Issues in MASH-ville: US Government Chaos and Scanning Market Dynamism

S6.13.2 - Newsmakers: Updating Our Approach to Screening for Advanced Liver Disease

S6.13.1 - Major Issues in MASH-ville: Developing a More Integrated Approach to MASH Patient Management

S6.13 - Locating MASH patients, Population Screening for Advanced Disease, Impact of Washington on Americans' Health

S6.12.3 - After the Semaglutide Approval: What Next For MASH Therapy?

S6.12.2 - After the Semaglutide Approval: Expanding MASH Awareness Will Change Medical Practices

S6.12.1 - After the Semaglutide Approval: Impact on Patients and Pharmacotherapy

6.12 - A Second US Drug Approval! What Semaglutide's Success Portends For MASLD Care in the US

6.11.3 - Expert: Emily Andaya Asks Why There Is No "L" In the (Multi-Meatbolic) CKM Initiative

6.11.2 - Multi-Metabolic Week Part II: Benefits of the Multi-Metabolic Approach

6.11.1 - Multi-Metabolic Week Part I: Role of MASLD In Multi-Metabolic Clinics

6.11 - Multi-Metabolic Practices Integrate MASLD with Other Non-Communicable Diseases

6.10.3 - Expert: Tim Jobson on Using Basic Data and Analytics to Identify At-Risk Patients

6.10.2 - Newsmakers: LiverRight Launches America's First Virtual Hepatology Clinic

6.10.1 - FIrst Six Months, Part I: The Promise of Proteomics For Developing Individualized Treatment Plans

6.10 - New Approaches to Patient Care: NIT-driven drug choices, Virtual Clinics, Large-Scale Screening

6.9.3 - Expert: Naim Alkhouri Discusses His Long Friendship with Stephen Harrison and His New Role at Summit Clinical Research

6.9.2 - Newsmaker: Fatty Liver Alliance President Mike Betel Discusses His 3rd Annual 30-Day Glucose Challenge

6.9.1 - #SLDThinkTank2025, Part III: Unique Challenge of Nutrition Management and Role Politicians Can Play

6.9 - Complexities of Behavior Change, Devices That Can Help, Future of Clinical Trials and MedEd

6.8.3 - Deep Dive into Drug Development IV: Other Modes Of Action; Metabolic vs. Pleiotropic Effects

6.8.2 - Newsmaker: GLI President and CEO Larry Holden discusses Changes in Washington and How We Can Proceed

6.8.1 - #SLDThinkTank2025 Part II: Complexities and Challenges of Behavior Change

6.8 - Hybrid Interventions; Washington Challenges; Two-Target Treatment

S6 - E7.3 - Deep Dive into Drug Development, Part III: NITs in Drug Development

S6 - E7.2 - Patient Advocate Jose Willemse on Patient-Centered Care

S6 - E7.1 - #SLDThinkTank2025 Part I: Hybrid Interventions Integrate AI and Human Care

S6 - E7 - Barcelona SLD Conference Highlight; NITs in Drug Development

S6 - E6 - Remembering Stephen Harrison and His Many Contributions to MASH

S6 - E5.2 - Newsmaker: Naga Chalasani on Real-World Experience Prescribing Resmetirom

S6 - E5.3 - Expert: Scott Friedman on Gene Therapy and Advances in Liver Science

S6 - E5.1 - FGF-21s and A Promising Future on Cirrhosis

S6 - E5 - Drug Development Week: FGF-21s, Cirrhosis, Resmiterom, Gene Therapies

S6 - E4.3 - Expert: Mazen Noureddin Reviews the Exciting MASLD Drug Development Environment

S6 - E4.2 - Newsmaker: Fatty Liver Alliance Founder Mike Betel Discusses the Increased Visibility of Patient Advocates

S6 - E4.1 - MASLD Drugs, SLD Spectrum Insights Suggest Bright Future

S6 - E4 - Reasons for optimism in MASLD drug development and patient advocacy

S6 - E3.3 - Expert: GLI's Jeff McIntyre discusses implications of FDA job cuts on MASH drugs

S6 E3.2 - Newsmakers: FibroSIGHT™ Brings Clinical Trial Analytics to the Clinic

S6- E3.1 - Roundtable: Spotting Tomorrow’s Trends in Today's MASLD Studies

S6 - E3 - Drugs and Diagnostics Evolve as the FDA Devolves

S6 - E2 - MetALD Epidemiology, MASLD Mortality and a PCP "Unicorn"

S6 - E1: Two Multispecialty February Conferences and Europe Prepares for Resmetirom

S5 - E26.5 - Looking Back at #TLM2024 - Promoting Healthy Livers and Looking Ahead to 2025

S5 - E26.4 - Looking Back at #TLM2024 - Patient Advocacy and Patient-Centric Trials

S5 - E26.3 - Looking Back at #TLM2024 - FGF-21 Agents and the FDA Corner

S5 - E26.2 - Looking Back at #TLM2024 - Patient Genotyping and MASH Clusters

S5 - E26.1 - Looking Back at #TLM2024 - Semaglutide Passes the ESSENCE Test

S5-26 - One Month Later: Looking Back at MASLD/MASH Coverage From The Liver Meeting 2024

S5 - E25 - Reviewing Expert Recommendations on the Use of Resmetirom

S4 - E24.5 - SurfingMASH Question of The Week: Keys to Improving Provider-Patient Communication

S5 - E24.4 - EASL Congress Six Weeks Later: Jeff McIntyre's Key Implications for GLI

S5 - E24.3 - EASL Congress Six Weeks Later: Jeff McIntyre's Key Takeaways

S5 - E24.2 - EASL Congress Six Weeks Later: Mathieu Petitjean's Key Implications

S5 - E24.1 - EASL Congress Six Weeks Later: Mathieu Petitjean's Key Takeaways

S5 - E24 - A view of MASLD: Looking back at EASL Congress from six weeks later

S5 SPECIAL 5 - Reviewing EASL Congress: Louise Campbell 3 (first-time material)

S5 SPECIAL 4 - Reviewing EASL Congress: Sven Francque

S5 SPECIAL 3 - Reviewing EASL Congress: Louise Campbell 2

S5 SPECIAL 2 - Reviewing EASL Congress: Louise Campbell I

S5 SPECIAL 1 - Reviewing EASL Congress: Mike Betel

S5 - E23.6 - From The Vault: Improving Patient Self-Management And Key Takeaways On Nutrition For MASH Resolution

S5 - E23.5 - From the EASL Congress: The Need for Shared Experience MASLD Support Groups and Programs

S5 - E23.4 - From the EASL Congress: Socioeconomic And Psychological Issues In The Physician-Patient Dialogue

S5 - E23.3 - From The EASL Congress: Improving The Physician-Patient Dialogue

S5 - E23.2 - From The EASL Congress: Dynamics Of The Physician-Patient Dialogue

S5 - E23.1 - From The EASL Congress: Overview Of Challenges In Physician-Patient Communication

S5 - E23 - Lessons from EASL Congress: Challenges in Provider-Patient Communication

S5 - E22.6 - FROM THE VAULT: Patient Advocates Reflect On How The "System" Views MASH

S5 - E22.5 - Healthy Livers, Healthy Lives: Watershed Moments To Come In MASLD Publlc Policy

S5 - E22.4 - Healthy Livers, Healthy Lives: The Role Of The Updated EASL MASLD Guidelines And Big Data

S5 - E22.3 - Healthy Livers, Healthy Lives: Challenges and Promise in Building a Global MASLD Health Policy

S5 - E22.2 - Healthy Livers, Healthy Lives: "Political Will" In MASLD Public Policy

S5 - E22.1 - Healthy Livers, Healthy Lives: Why MASHville Needs This Coalition

S5 - E22 - Healthy Livers, Healthy Lives: A Global SLD Public Health Coalition

S5 - E21.6 - From The Vault: Comments On The 2023 AASLD Revised Practice Guidance

S5 - E21.5 - The Updated MASLD CPG: Implications For Healthcare Systems

S5 - E21.4 - The Updated MASLD CPG: Pharmacology And New Educational Needs

S5 - E21.3 - The Updated MASLD CPG: Screening, Diagnosing And Managing Patients

S5 - E21.2 - The Updated MASLD CPG: Benefits Of The Collaboration

S5 - E21.1 - The Updated MASLD CPG: Introductions

S5 - E21 - Reviewing The Updated ESL-EASD-EASO MASLD Clinical Practice Guidelines

S5 - E20.6 - From the Vault: FGF-21s and "Twin-cretins" At EASL Congress 2023

S5 - E20.5 - Drug Development Highlights From EASL Congress 2024: Denifenstat, SPECIAL and Other Stories

S5 - E20.4 - Drug Development Highlights From EASL Congress 2024: Are FGF-21s Induction Therapy or a "MASH Cure"?

S5 - E20.3 - Drug Development Highlights From EASL Congress 2024: "Twin-cretins" and efruxifermin

S5 - E20.2 - Drug Development Highlights From EASL Congress 2024: Tirzepatidate and other "Twin-cretins"

S5 - E20.1 - Drug Development Highlights From EASL Congress 2024: Resmetirom

S5 - E20 - Lessons From EASL Congress 2024: Exciting Advances in Drug Development

EASL Congress 2024: Interviews From A Seminal Meeting For MASLD & MASH

S5 - E18.5 - How Listeners Can Support HOPE, A Unique Support Community For People Who Have Harmed Their Bodies Through Alcohol Use Disorder

S5 - E18.4 - The Future Of HOPE: Expanding the Support Community for Patients Who Have Harmed Their Bodies Through Alcohol Use Disorder

S5 - E18.3 - Specific Support Elements HOPE Provides For People Who Have Harmed Themselves Due To Alcohol Use Disorder

S5 - E18.2 - Why People Who Have Harmed Themselves Through Alcohol Use Disorder Need HOPE

S5 - E18.1 - Introducing HOPE, A Project For People Who Have Harmed Their Bodies Through Alcohol Use DIsorder

S5 - E18 - Introducing HOPE, a support program for patients living with the effects of ALD and cirrhosis

S5 - E17.6 - From The Vault: Looking Back At The EASL Congress 2023 Preview & Program Design

S5 - E17.5 - Previewing EASL Congress 2024: Focusing On MASLD Drug Development

S5 - E17.4 - Previewing EASL Congress 2024: Is Big Data The Future Of MASLD?

S5 - E17.3 - Previewing EASL Congress 2024: Jörn Schattenberg Joins The MASLD Conversation

S5 - E17.2 - Previewing EASL Congress 2024: Collegiality, Consortia & High-Quality MASLD Abstracts

S5 - E17.1 - Previewing EASL Congress 2024: Secretary General Aleksander Krag Shares His Vision For The Congress

S5 - E17 - Previewing EASL Congress 2024 and its Major MASLD Moments

S5 - E16.5 - From The Vault: Stephen Harrison Discusses FASCINATE-2 Results For Denifenstat

S5 - E16.4 - Remembering MASLD Master Stephen Harrison: Stephen As Role Model

S5 - E16.3 - Remembering MASLD Master Stephen Harrison: Stephen As Innovator

S5 - E16.2 - Remembering MASLD Master Stephen Harrison: Stephen As Patient Advocate

S5 - E16.1 - Remembering MASLD Master Stephen Harrison: Stephen As Integrator

S5 - E16 - Remembering Stephen Harrison 2: More Memories of a MASLD Master

S5-15.6 - From the Vault: Discussing NAIL-NIT Findings at INCBCN 2023

S5 - E15.5 - From SLD Think-Tank 2024 Wrap-Pp: Shall We Focus More on Preventive Hepatology?

S5 - E15.4 - From SLD Think-Tank 2024: Improving Preparedness And The Value of Having Rezdiffra

S5 - E15.3 - From SLD Think-Tank 2024: Meeting Agenda And The "Magic Wand"

S5 - E15.2 - From SLD Think-Tank 2024: An Innovative Stimulating Meeting Design

S5 - E15.1 - From SLD Think-Tank 2024: Meet Maja Thiele And Learn About LiverAIM

S5 - E15 - Highlights from SLD Think-Tank 2024, a Public Health Approach to MASH

S5 - E14.4 - From the Vault: Our Last Year-End Interview With MASH Master Stephen Harrison

S5 E14.2 - Remembering Stephen Harrison: Professional Accomplishments

S5 E14.1 - Remembering Stephen Harrison: Personal Memories

S5 - E14.3 - Remembering Stephen Harrison: "Harrisonisms"

S5 - E14 - Remembering Stephen Harrison - colleagues share memories and impressions of an SLD master

S5 - E13.6 - One Year Ago: When Global Fatty Liver Day Was #NASHDay 2023

S5 - E13.5 - MASH And The Elephant Metaphor: Attacking A Multi-Faceted, Complex Disease

S5 - E13.4 - A Deeper Dive into Care Challenges and Barriers Affecting MASH Patient Care

S5 - E13.3 - Practical Challenges In Patient Care: Role Of GLP-1s And Scanning

S5 - E13.2 - Global Fatty Liver Day 2024 And The Rationale Behind "Act Now. Get Screened."

S5 - E13.1 - Remembering SurfingMASH Co-Founder Stephen Harrison

S5 - E13 - Previewing Global Fatty Liver Day 2024

S5 - E12.6 - From The Vault: More Different Roles For NITs In MASH

S5 - E12.5 - MASH Drug Development: Combining With Old Drugs And Shortening Time To Approval

S5 - E12.4 - MASH Drug Development: Implications Of Concomitant Metabolic Therapy Use

S5 - E15.3 - MASH Drug Development: Improvement Since 2020 And Issues That Remain

S5 - E12.2 - MASH Drug Development: Improving Efficacy Endpoints

S5 - E12.1 - MASH Drug Development: The State Of The Graveyard 2023

S5 - E12 - MASH Drug Development: What Failures Taught Us About Success

S5 - E11.6 - From The Vault: Another Strategic Role For Prescribing MASH Drugs

S5 - E11.5 - MASH Prescribing Models & The Increasing Challenge Of Keeping Patients In Long-Term Clinical Trials

S5 - E11.4 - More Hot MASLD Topics: Inflammation, MD columnists' Advice, FGF-21s

S5 - E11.3 - Panelists' Hot Topics: Low-Dose Aspirin, SLD Think Tank, Dietary Inflammation Index

S5 - E11.2 - Defining Therapeutic Futility For Rezdiffra And Discussing Advances In MASLD Translational Medicine

S5 - E11.1 - How The Rezdiffra Approval Has Affected How One Clinic Manages MASH Patients

S5 - E11 - Life With Rezdiffra: Early Impact On MASH Patient Treatment and MASLD Clinical Trials

S5 - E10 - Lessons And Insights On Using Basic EHR Data To Screen For Target MASLD Patients

S5 - E9.6 - From The Vault: An Earlier Look At Screening In The Clinical Care Pathway

S5 - E9.5 - In-Office Screening Post-Rezdiffra: The Importance Of Predictive Biomarkers

S5 - E9.4 - In-office MASLD Screening and the Clinical Care Pathway

S5 - E9.3 - How Will Increased Access To In-Office Scanning Improve MASLD Therapy:

S5 - E9.2 - VCTE Studies Demonstrate That Multiple Nutrition Interventions Can Support MASLD Patients

S5 - E9.1 - VCTE As A Prognostic And Therapeutic Tool For MASLD

S5 - E9 - Value of VCTE Or Other In-Office MASLD Monitoring

S5 - E8 - Changing Patient Incentives For Participating In MASH Clinical Trials

S5 - E7.6 - MASLD Patient Advocates' Recommendations for Others after Rezdiffra Approval

S5 - E7.5 - Will Increasing the Focus on MASH via Rezdiffra Overwhelm the Healthcare System?

S5 - E7.4 - How MASH patient advocates plan to support Rezdiffra

S5 - E7.3 - Patient advocacy and the Rezdiffra label

S5 - E7.1 - Rezdiffra is approved! How patient and their advocates processed the news about the first MASH drug

S5 - E7.2 - Identifying the target MASH patients for Rezdiffra

S5 - E7 - MASLD Patient Advocates Celebrate Rezdiffra and Discuss the Future

S5 - E6.6 - Closing Question From The Episode On Rezdiffra, The First MASH Drug

S5 - E6.5 - BioPharma Industry Takeaways ForBioPharma Industry Takeaways From The Rezdiffra Launch The Rezdiffra Launch

S5 - E6.4 - Finding The MASH Patients That Are The Initial Rezdiffra Targets

S5 - E6.3 - Staging and screening patients for Rezdiffra using NITs

S5 - E6.2 - How Approval Of Rezdiffra,The First MASH Drug, Might Improve Patient Adherence To Lifestyle Recommendations

S5 - E6.1 - Rezdiffra Is Approved! How Key Opinion Leaders Processed The News About The First MASH Drug

S5 - E6 - Rezdiffra Is Here! Key Opinion Leaders React To The First MASH Drug Approval

S5 - E5.6 - From The Vault: Tsunami's First Look At MASEF, A Major New NIT

S5 - E5.5 - More on GLP-1s and a Broader MASH Wrap-up

S5 - E5.4 - The dance of drug pricing and patient targets in MASH, PLUS: the role of GLP-1s

S5 - E5.3 - Strategies to Improve NIT reliability in Diagnosing and Staging MASH Fibrosis

S5 - E5.2 - NITs In The Diagnosis and Treatment Of Advanced MASH Fibrosis Patients

S5 - E5.1 - Why We Are Focusing On NITs For MASH Diagnosis And Screening

S5 - E5 - How Non-Invasive Tests (NITs) For MASLD And MASH Might Evolve In 2024

S5 - E4.6 - From The Vault: What a NASH Disease Model Reveals About Treating Advanced Fibrosis

S5 - E4.5 - MASH Education As A Tool To Stem The MASLD Pandemic

S5 - E 4.4 - Learning about the Global NASH Council's work in MASLD

S5 - E4.3 - Slowing The Growth Of The MASLD Pandemic

S5 - E4.2 - The Breadth Of MASLD Disease Burden And Cost Effectiveness Of Therapies

S5 - E4.1 - Appreciating The Disease Burden Of MASLD

S5 - E4 - MASLD Epidemiology Takes: Rapidly Proliferating Prevalence; Many Public Health Needs

S5 - E3.6 - From the Vault: EASL Congress 2023: Focus On The New MASLD Nomenclature

S5 - E3.5 - The New MASLD Nomenclature: What Lies Ahead For MASH Patients And Providers?

S5 - E3.4 - Discussing MASLD With Patients: MASH Is Not "Just A Little Fat" Any More

S5 - E3.3 - The New MASLD Nomenclature -- MASLD Rollout And Stakeholder Roles

S5 - E3.2 - How Did The Delphi Process Work For The New MASLD Nomenclature?

S5 - E3.1 - Why create a new MASLD nomenclature?

S5 - E3 - The New MASLD Nomenclature And How We Got Here

S5 - E2.5 - Conversations From The Vault: Jeff McIntyre On ICER Reviews And NITs

S5 - E2.4 - MASLD Patient Advocates' Priority 2024 MASH Programs

S5 - E2.3 - Where Do MASLD Patients And Advocates Fit In MASH Drug Access Decisions?

S5 - E2.2 - After The First MASH Drug Approval, Focus Shifts To Patient Access

S5 - E2.1 - Expectations For The Resmetirom PDUFA Date - The First MASH Drug Approval?

S5 - E02 - MASLD Patient Advocates Plan MASH Activities For 2024

S5 - E1.6 - SurfingMASH Is Back! How Can Consumer Behavior Confound MASH Care?

S5 -E1.5 - SurfingMASH Is Back! How Will GLP-1 Ads From Telemedicine Affect MASH?

S5 - E1.4 - SurfingMASH Is Back! Reframing "Liver Awareness" In The Context Of US DTC Advertising

S5 - E1.3 - SurfingMASH Is Back! 2024 Podcast Updates And The Increasing Need For "Liver Awareness"

S5 - E1.2 - SurfingMASH Is Back! Louise Campbell Discusses Building MyLife365.Me And Expanding To New Markets

S5 - E1.1 - SurfingMASH Is Back! Jörn Schattenberg On Becoming Department Director At Saarlands

S5 - E1 - How might approval of a MASH drug affect patient treatment?

S4 E50.11 - Wrapping Up 2023 - An Interview with Global Liver Institute Vice President, Liver Health Programs, Jeff McIntyre

S4 E50.10 - Wrapping Up 2023 - An Interview with Ukraine Public Health Executive Tetiana Deshko

S4 E50.9 - Wrapping Up 2023 - An Interview With Novo Nordisk International Medical VP Michelle Long

S4 E50.8 - Wrapping Up 2023 - An Interview With Biotech Entrepreneur Rachel Zayas

S4 E50.7 - Wrapping Up 2023 - An Interview with Donna Cryer

S4 E50.6 - Wrapping Up 2023 - An Interview With Neeraj Mistry And Jenn Leigh Jones

S4 E50.5 - Wrapping Up 2023 - An Interview with Hannes Hagstrom

S4 E50.4 - Wrapping Up 2023 - An Interview With Dean Tai

S4 E50.3 - Wrapping Up 2023 - An Interview With Naim Alkhouri

S4 E50.2 - Wrapping Up 2023 - An Interview with Mike Betel and Tony Villiotti

S4 - E50.1 - Wrapping Up 2023 in Steatotic Liver Disease: A Discussion with Jeff Lazarus

S4-E49.6 - Conversations From The Vault -- NITs At TLM2022

S4-E49.5 - TLM2023 Wrap-Up - Panel Discusses New Nomenclature, Impact Of Triple Agonists

S4-E49.4 - TLM2023 Wrap-Up - Panel Discusses Liver Science, Other Issues

S4-E49.3 - TLM2023 Wrap-Up - Panel Discusses NITs, AI And Bariatric Surgery

S4-E49.2 - TLM2023 Wrap-Up - Panel Discusses Medicines

S4-E49.1 - TLM2023 Wrap-Up - Panel Discusses General Impressions

S4-E49 - Wrapping Up TLM 2023 - A Panel Discussion With Scott Friedman And Laurent Castera

S4-E48.3 - Reviewing TLM 2023 Part One (cont.) – A Discussion with Michael Betel

S4-E48.2 - Reviewing TLM 2023 Part One (Cont.) - A Discussion With Tim Jobson

S4-E48.1 - Reviewing TLM 2023 Part One -- A Discussion With Zobair Younossi

S4-E47 - Previewing The Liver Meeting 2023: Abstracts of Interest

S4-E46.3 - The Liver Meeting 2023: Updates with Key Opinion Leader, Naim Alkhouri

S4-E46.4 - The Liver Meeting 2023: Updates with Key Opinion Leader, Scott Isaacs

S4-E46.2 - Anticipating TLM 2023 with Michael Betel

S4-E46.1 - The Liver Meeting 2023: Updates with Key Opinion Leader, Jörn Schattenberg

S4-E45.4 - From the Vault: Tetiana Deshko on the public health care in Ukraine during the invasion

S4-E45.3 - The Impact of War on a Leading Clinical Trial Site

S4-E45.2 - Hepatology Under Air Raids

S4-E45.1 - Meeting Professor Oren Shibolet

S4-E45 - Interview with Oren Shibolet, Head of Gastroenterology and Hepatology at the Tel Aviv Medical Center

S4-E44.5 - From the Vault: Creating An Early Diagnosis NASH Decision Model

S4-E44.4 - How does MASH and MASLD differ in women compared to men?

S4-E44.3 - Roberta Forlano on Different Challenges for Different Patient Populations

S4-E44.2 - Investigating False Negative Screening Rates

S4-E44.1 - Introducing Roberta Forlano and a Variety of Compelling Research Interests

S4-E44 - Screening Strategies for Gender-Based SLD Challenges

S4-E43.6 - Career Advice on Academia vs Corporate Life

S4-E43.5 - Corporate life vs academia: which is right for who?

S4-E43.4 - Michelle Long on Academia vs Industry

S4-E43.3 - Rachel Zayas on the Trajectory of and Intentionality Behind AGED Diagnostics

S4-E43.2 - CEO Rachel Zayas on Fundraising and Venture Competitions

S3-E43.1 - Rachel Zayas on the Product Development Process of AGED Diagnostics

S4-E43 - Focus on Career Stories and Entrepreneurship

S4-E42.6 - From the Vault: NAFLD Summit in Context and Learning from Failed Trials

S4-E42.5 - Final Recap of the 2023 SLD Summit: Takeaways and Looking Forward

S4-E42.4 - Hannes Hagström on the Broad Aperture of the SLD Summit

S4-E42.3 - Diving into Research from the EASL SLD Summit

S4-E42.2 - MASH, MetALD and Alcoholic SLD: A Continuum?

S4-E42.1 - Sven Francque on Organizing the EASL SLD Summit

S4-E42 - EASL SLD Summit 2023

S4-E41.6 - From the Vault: Highlights from Paris NASH 2021

S4-E41.5 - Veronica Miller on “why are we validating a surrogate with a surrogate?”

S4-E41.4 - NITs to Qualify Patients for Trials vs to Evaluate Efficacy of Drugs

S4-E41.3 - Laurent Castera on the FDA's NIT Workshop

S4-E41.2 - Naim Alkhouri on clinical trial populations and the future decisions of FDA

S4-E41.1 - Naim Alkhouri on an NIT-based alternative path to conditional approval

S4-E41 - Reviewing the FDA's NIT Workshop

S4-E40.5 - Paris NASH Review: More Topics and Final Thoughts

S4-E40.4 - Challenges in Treating and Assessing Adequately

S4-E40.3 - Which test is best for which patients?

S4-E40.2 - Deeper Dive into the Landscape of NITs

S4-E40.1 - Liver as a Regenerative Organ and the Use and Limitations of NITs

S4-E40 - Review of Paris NASH 2023

S4-E39.4 - MASEF: Where will we be in 2 years?

S4-E39.3 - MASEF: Next Steps and New Cohorts

S4-E39.2 - MASEF: Cost Effectiveness and Application Settings

S4-E39.1 - MASEF: Study Parameters and Notable Results

S4-E39 - The Metabolomics-Advanced Steatohepatitis Fibrosis Score (MASEF)

S4-E38.4 - On the Capabilities of The Health Care Systems

S4-E38.3 - Getting the Right Message to the Right Patient at the Right Time

S4-E38.2 - On the Importance of Multidisciplinary Teams

S4-E38.1 - 3 Important Questions to Consider for Full Patient Support

S4-E38 - Nurses Helping NASH Patients

S4-E37.4 - NASH Patient Care: The Value of Patient Education

S4-E37.3 - NASH Patient Education: Liver Nurses’ Roles

S4-E37.2 - NASH Patient Support: Liver Nursing Challenges

S4-E37.1 - NASH Patient Support: Meet Today’s Liver Nurses

S4-E37 - Focus on the Role of Allied Health and Strengthening NASH Education

S4-E36.6 - From the Vault: NASH Challenges: Early Diagnosis & NASH Patient Management

S4-E36.5 - LOCATE-NAFLD: What’s Next and Practical Takeaways

S4-E36.4 - LOCATE-NAFLD: Funding and Generating Data

S4-E36.3 - LOCATE-NAFLD: Cost Effectiveness and Implementation in Different Systems

S4-E36.2 - LOCATE-NAFLD: Study Design and Early Analysis

S4-E36.1 - Meeting James O’Beirne and Introducing the LOCATE-NAFLD Study

S4-E36 - LOCATE-NAFLD: Improved Models for Patient Identification and Risk Stratification

S4-E35.4 - Looking Forward at the SurfingNASH Program

S4-E35.3 - Strengthening Patient Involvement, NIT Development and Lessons from AI

S4-E35.2 - Challenges Associated with Communicating New Nomenclature

S4-E35.1 - High-Level Recap of Two Key Events for 2023 Thus Far

S4-E35.5 - From the Vault: The Psychology of Decision-Making Around Diet and Professional Support

S4-E35 - SurfingNASH 2023 Year-to-Date Review and Looking Ahead

S4-E34.6 - From the Vault: Presentation on Efruxifermin in NASH with Fibrosis

S4-E34.5 - GLP-1s and Lean Muscle Loss

S4-E34.4 - Pemvidutide and the Importance of the Actual GLP-1-to-Glucagon Impact Ratio

S4-E34.3 - The Increasing Importance of Omics

S4-E34.2 - Practical and Plausible Notes On Injectables Versus Oral Agents

S4-E34.1 - The Excitement of FASN Inhibitors: Positive 2B Interim Data for Denifanstat

S4-E34 - Drug Development Stories from EASL and ADA: Part 2

S4-E33.5 - From the Vault: ILC 2022 Looking Back: NASH Is a Complex Disease

S4-E33.4 - More Presentation Insights on Frequency of Testing, NITs and Biopsy

S4-E33.3 - Steatotic Liver Disease, HCC and Mechanisms of Fibrosis Resolution

S4-E33.2 - Unmet Needs in the Primary Care Setting for Disease Identification

S4-E33.1 - EASL Congress 2023: Focus on New Nomenclature

S4-E33 - EASL Congress: Nomenclature and More Compelling Presentations

S4-E32.5 - From the Vault: ILC 2022 Looking Back: Crystal Balling & The Semaglutide Trial

S4-E32.4 - The Potential of NASH Drugs as Adjuvant Therapy

S4-E32.3 - Discussing Other Drugs in the Therapeutic Landscape

S4-E32.2 - Why We Should Develop Deeper Understanding of Liver Volume

S4-E32.1 - Lead Principle Investigator Stephen Harrison Recaps the MAESTRO-NASH Program for Resmetirom

S4-E32 - Drug Development Stories from EASL and ADA: Part 1

S4-E31.4 - EASL Congress and ADA Scientific Sessions: Reshaping the way we think about Fatty Liver Disease

S4-E31.3 - Jörn Schattenberg on the Therapeutic Landscape and Fibrosis Resolution

S4-E31.2 - What do we know about mechanisms of action in NASH drugs and the commercial implications?

S4-E31.1 - Mazen Noureddin on "NASH Monopoly"

S4-E31 - Mazen Noureddin and Jörn Schattenberg on the Developing Therapeutic Landscape

S4-E30.4 - EASL Congress 2023: Final Takeaways

S4-E30.3 - EASL Congress 2023: More Posters and Presentations

S4-E30.2 - EASL Congress 2023: Scoring Systems to Evaluate NASH

S4-E30.1 - EASL Congress 2023: Nomenclature Rollout

S4-E29.3 - EASL Congress 2023: Final Thoughts on Days 1-3

S4-E29.2 - EASL Congress 2023: Challenges in Patient Screening and the “2nd Wave” of NASH Therapeutics

S4-E29.1 - EASL Congress 2023: Presentation on MAESTRO-NASH Phase 3 Results

S4-E30 - EASL Congress 2023: Real-Time Review Part 2

S4-E29 - EASL Congress 2023: Real-Time Review Part 1

S4-E28 - Tetiana Deshko on the public health care in Ukraine during the invasion

S4-E27.6 - Deep Dive into AI and Pathology with Arun Sanyal and David Kleiner

S4-E27.5 - EASL Congress 2023: Exploring Technology for Identifying Patients

S4-E27.4 - Previewing EASL Congress 2023 with Louise Campbell: Frontline Screening

S4-E27.3 - Abstract session - NAFLD: Clinical Aspects

S4-E27.2 - Abstract session - NAFLD: Therapy

S4-E27.1 - Unpacking the Program with Ian Rowe and Jörn Schattenberg

S4-E27 - EASL Congress 2023 Preview: Great Talks to Anticipate!

S4-E25.5 - Wrap-Up on NICE Guidance for FibroScan

S4-E25.4 - NICE Guidance for FibroScan: The Devil is in the Details

S4-E25.3 - The Future of FibroScan and Optimizing Availability of Quality Scanning

S4-E25.2 - NICE Guidance for FibroScan: Collecting Data Well and Wisely

S4-E25.1 - Meeting Vanessa Hebditch and the Role of the British Liver Trust in Fighting for FibroScan

S4-E26.4 - International #NASHDay 2023 Wrap-Up

S4-E26.3 - FibroScan and the Impact of Socioeconomic Factors on Liver Health

S4-E26.2 - Discussing the Rise of NAFLD/NASH in Adolescents

S4-E26.1 - What Patient Advocate Organizations Are Doing Around the World in Support of #NASHDay 2023

S4-E26 - Patient Advocate Focus on International #NASHDay 2023

S4-E25 - Exciting News! NICE Guidance Supports FibroScan Use Outside Secondary and Specialist Care in the UK

S4-E24.6 - From the Vault: Did the Innovations in NAFLD Care Conference Strengthen the Case for an Integrated NAFLD Care Pathway?

S4-E24.5 - INCBCN Review: Wrap-Up Comments and Moving Forward

S4-E24.4 - INCBCN Day 2 Summary

S3-E24.3 - Focus on Preventative Hepatology

S4-E24.2 - INCBCN Review: NAFLD and Social Drinking

S4-E24.1 - INCBCN Review: NASH-NITs Real-World-Evidence Summit

S4-E24 - Reviewing the 2023 Innovations in NAFLD Care Workshop

S4-E21.5 - From the Vault: ILC 2022 Looking Back: NASH Is a Complex Disease

S4-E21.4 - Virtual EASL Congress 2023 and the Power of Posters

S4-E21.3 - Curating the EASL 2023 Program and 3 “Can’t Miss” Features

S4-E21.2 - Previewing EASL Congress 2023: Highlighting Exciting Elements

S4-E21.1 Meeting Aleksander Krag and Setting the Stage for EASL Congress 2023

S4-E23.4 - Deep Dive into Hepatocellular Ballooning and the Power of AI

S4-E23.3 - Lowering Screen Fail Rates and Guidelines for the Biopsy Reading Process

S4-E23.2 - The Future of AI-Assisted Digital Pathology and NITs

S4-E23.1 - Obeticholic Acid: Is the Juice Worth the Squeeze?

S4-E23 - Stephen Harrison on Challenges and Opportunities in NASH Drug Development

S4-E22 - PART 1: FDA ADCOM Meeting for Obeticholic Acid as a Treatment for Pre-Cirrhotic Fibrosis Due to NASH

S4-E21 - Surfing NASH Previews EASL Congress 2023

S4-E20.6 - From the Vault: Discussing NITs and Final Thoughts on NAFLD Summit

S4-E20.5 - Harnessing the Strengths of the Patient Advocate Community

S4-E20.4 - Donna Cryer’s Call to Action for Patient Advocacy in the NASH Community

S4-E20.3 - Generating and Promoting the Data to Demonstrate Patient Needs

S4-E20.2 - Listening to Both Sides: Allied Health for Patient Empowerment

S4-E20.1 - Who is going to be the Larry Kramer of NASH?

S4-E20 - Leveraging Patient Voice and Needs in the NASH Community

S4-E19.6 - From the Vault: REGENERATE Redux: Clearing The Finish Line?

S4-E19.5 - Teasing the Difference Between Patient Advocate Voice and Patient Advocate Vote

S4-E19.4 - Patient Advocates Describe the Reasoning Behind Their Testimonies

S4-E19.3 - The Role of Biopsy in Prescribing NASH Therapeutics

S4-E19.2 - Patient Advocates React to the Word “Empathy”

S4-E19.1 - How Did the Patient Advocates Come to Offer Testimonies?

S4-E19 - Patient Advocate Panel Responds to ICER Draft Report on Resmetirom and Obeticholic Acid for NASH

S4-E18.6 - From the Vault: Clinical Care Pathway: What Can Be Done Today?

S4-E18.5 - Allied Health Professionals and Patient Identification in Endocrinology Clinics

S4-E18.4 - Empowering Physicians Through Simple Tools and the Demise of Beethoven

S4-E18.3 - Positive Patient Engagement with Biofeedback and NAFLD/NASH in Chronic Kidney Patients

S4-E18.2 - Risk Stratification and Identification of NAFLD/NASH Patients in the Endocrinology Setting

S4-E18.1 - Meeting Cyrielle Caussy at the Intersection of Endocrinology and Hepatology

S4-E18 - Interplay of Endocrinology and Hepatology in Treatment and Knowledge Development

S4-E17.8 - Predictions for the Surfing NASH 6th Anniversary Special

S4-E17.7 - Discussing the Drug Development Landscape and Growing Community Education

S4-E17.6 - The Trajectory of Liver Science: How Far Have We Come?

S4-E17.5 - Surfer Throwbacks: Meeting the Co-Hosts for the First Time

S4-E17.4 - Stephen Harrison on Improving Clinical Trial Enrollment and Reminiscing on the Podcast’s Early Days

S4-E17.3 - Surfing NASH 3rd Anniversary Special: Interview with Frédéric Cren of Inventiva Pharma

S4-E17.2 - Surfing NASH 3rd Anniversary Special: Interview with Donna Cryer of the Global Liver Institute

S4-E17.1 - Surfing NASH 3rd Anniversary Special: Interview with Amy Articolo of Novo Nordisk

S4-E17 - Surfing the NASH Tsunami 3rd Anniversary Special

S4-E16.6 - From the Vault: #NASHDay 2022: SurfingNASH Wrap-Up

S4-E16.5 - How Do We Step Up to NASH?

S4-E16.4 - #NASHDay and Activating Awareness Across Communities

S4-E16.3 - The Untapped Potential of the Liver Community

S4-E16.2 - #NASHDay 2023 Theme: Step Up to NASH!

S4-E16.1 - What Makes This #NASHDay Different From Previous Years?

S4-E16 - Stepping Up to International #NASHDay 2023

S4-E15.5 - From the Vault: Advancing NASH Best Practices In NITs: “Stacking” NASH Biomarkers

S4-E15.4 - Final Takeaways from Liver Forum 14 and Reviewing the Published Slides

S4-E15.3 - Session VIII: Stretch Exercise: New Look at Statistics

S4-E15.2 - Liver Forum 14: Panelists Select Sessions of Interest

S4-E15.1 - What is The Liver Forum and Initial Impressions

S4-E15 - Review of Liver Forum 14

S4-E14.4 - International NASH Day 2023 and the Surfing NASH 3rd Anniversary

S4-E14.3 - Drug Development News: Phase 3 Press Releases on the Horizon

S4-E14.2 - NICE and FibroScan for Primary Care: Utilizing Early Detection to Prevent Cirrhosis

S4-E14.1 - Discussing the 3rd Annual Liver Connect Conference

S4-E14 - Co-Host Roundtable on the Liver Connect Conference, FibroScan and Pathways, Therapeutic News and More

S4-E13.6 - From the Vault: Innovations in NAFLD Care Conference: What Is the Importance of Steatosis in Metabolic Health?

S4-E13.5 - INCBCN 2023: What Will Be Its Impact?

S4-E13.4 - INCBCN 2023: Not Your Average Conference

S4-E13.3 - Discussing the Day 2 Program of INCBCN in Barcelona

S4-E13.2 - Linking NAFLD and NASH to Cancer and Educating on Fatty Liver Screening

S4-E13.1 - Feedback from the Inaugural INCBCN and Setting the Stage for the 2023 Workshop

S4-E13 - Previewing the 2023 Innovations in NAFLD Care Workshop

S4-E12.6 - From the Vault: Building a Disease Model for NASH Prevalence: Key Challenges

S4-E12.5 - ICER Draft Report: Different Stakeholder Impacts

S4-E12.4 - Biopsy, Biomarkers and Assessing the Value and Pricing of New Medications

S4-E12.3 - Keeping Regulatory Pace with Field Advancements

S4-E12.2 - ICER Draft Report: Assessment of Disease Prevalence and Prospective Drug Efficacy

S4-E12.1 - Introducing the ICER Draft Report on Resmetirom and Obeticholic Acid for NASH

S4-E12 - Deep Dive: ICER Draft Report on Resmetirom and Obeticholic Acid for NASH

S4-E11.6 - From the Vault: #NASHDay 2022 Preview: SurfingNASH Predictions

S4-E11.5 - Excitement and Trepidations: Exploring the Year Ahead in Fatty Liver

S4-E11.4 - Increasing Incidence of Type-2 Diabetes Among Adolescents

S4-E11.3 - Fighting for Fair Regulation Around What’s Deemed “Healthy”

S4-E11.2 - Pricing Estimates for Imminent Drug Approvals and the Future Standard of NITs

S4-E11.1 - The Surfers Highlight What’s Happening for Fatty Liver in 2023

S4-E11 - The Yin and Yang of Technology and Regulation

S4-E10.5 - From the Vault: 2022 Liver Conference: Pediatric NAFLD and Liver Health Education

S4-E10.4 - Pediatric and Adolescent Fatty Liver: Impact of Emerging Drugs and Trials

S4-E10.3 - Pediatric and Adolescent Fatty Liver: Implementing Real World Interventions

S4-E10.2 - Pediatric and Adolescent Fatty Liver: Cardiometabolic Complications and Challenges in NITs

S4-E10.1 - Increasing Incidence of Pediatric and Adolescent Fatty Liver

S4-E10 - Focus on Pediatric and Adolescent Fatty Liver Disease

S4-E9.5 - From the Vault: Discussing Comprehensive Care Models For NAFLD: Metrics, Key Performance Indicators and Improving Management

S4-E9.4 - Combating Swelling NAFLD and NASH Prevalence: Drugs, Diagnostics and Guidelines for the Frontline

S4-E9.3 - Diabetes Drug Choices With Benefits For NAFLD

S4-E9.2 - What’s Behind The New AACE Fatty Liver Guidelines?

S4-E9.1 - Growing NAFLD-Diabetes Dual Prevalence Increases CVD Risk for Diabetics

S4-E9 - From the Getting Ahead of the Rising Tide Series: Challenges as a Leading Patient Advocate is Screened

S4-E8.6 - From the Vault: Previewing Innovations in NAFLD Care 2022: Day Two Sessions

S4-E8.5 - The Future of Digital Therapeutics

S4-E8.4 - Digital Apps: Patient Participation and Regulatory Challenges

S4-E8.3 - Joe Rubinsztain on ChronWell and Scalable Technology

S4-E8.2 - Feasibility Study: Cognitive Behavior Therapy for Improved Liver Health

S4-E8.1 - Utilizing Prescription Digital Therapeutics to Combat Fatty Liver

S4-E8 - Focus on Digital Health with Better Therapeutics and ChronWell

S4-E7.6 - From the Vault: What’s next in Driving the Global Public Health Agenda for NAFLD?

S4-E7.5 - Introducing the Rising Tide Podcast and Closing Comments on AASLD Guidance

S4-E7.4 - AASLD Practice Guidance and Its Influence Outside of the US

S4-E7.3 - AASLD Guidance and the Practical Impact on Patients Today

S4-E7.2 - Discussing ALT Cut Off and Utilizing FIB-4 in Primary Care

S4-E7.1 - Introduction to the AASLD Practice Guidance: Impressions and Overview

S4-E7 - New 2023 AASLD Practice Guidance

S4-E6.5 - From the Vault: How NAFLD Patient Advocacy Works: Two Key Pieces

S4-E6.4 - Accessing New Drugs and the Future of Fatty Liver for Australians

S4-E6.3 - Linking Cardiovascular Outcomes to Fatty Liver and Utilizing FIB-4 in Australia

S4-E6.2 - Mapping Fatty Liver in Australia: Prevalence and Subpopulations

S4-E6.1 - Tony Rahman on Fatty Liver Prevalence in Australia

S4-E6 - Introduction to NAFLD and NASH in Australia

S4-E5.6 - From the VAULT: Patient Follow-Up Challenges in Modeling NASH Diagnostics

S4-E5.5 - Wrap-Up on Data Aggregation and Transparency, Patient Feedback and More

S4-E5.4 - Patient Data: Security Issues and Proactivity for Empowerment

S4-E5.3 - Predictive Health Intelligence: Exploring Areas of Application

S4-E5.2 - How the Predictive Health System Works: Algorithms and Economic Pressures

S4-E5.1 - Creating a "Combined Informatics and Clinical Program"

S4-E5 - Predictive Health Intelligence: Using Historic Blood Test Results to Identify Risk of Fatty Liver

S4-E4.6 - Donna Cryer on Aligning Regulatory Science and Expanding Avenues for Advocacy

S4-E4.5 - Patient Advocates on “Getting the Message Out” as Approval of Drugs Approaches

S4-E4.4 - NASH-TAG 2023: Emerging Optimism from a Watershed Moment

S4-E4.3 - Surfing NASH Community Interview with Caitlin Schneider of Sonic Incytes

S4-E4.2 - Surfing NASH Community Interview with Jerry Mabary of Chronwell

S4-E4.1 - Surfing NASH Community Interview with Pamela Danagher of Terns Pharmaceuticals

S4-E4 - Surfing NASH Audience Reacts to NASH-TAG and the Future of Fatty Liver

S4-E3.6 - Interview with Co-founder & CSO of HistoIndex, Dean Tai, on AI-Assisted Histology

S4-E3.5 - NASH-TAG Review: Donna Cryer on “Good Regulatory Science”

S4-E3.4 - NASH-TAG Review: Insights on the F3 Population and AI-Assistance for Improving Therapeutic Efficacy

S4-E3.3 - NASH-TAG Review: Unpacking Resmetirom Data and Drinking from a Firehose

S4-E3.2 - NASH-TAG Review: NITs, Clinical Trial Design and Addressing “Indeterminate Zones”

S4-E3.1 - NASH-TAG Review: Patient Advocate Panel on Influence of New Drugs and Interprofessional Collaboration

S4-E3 - NASH-TAG Wrap-Up: Therapeutic Efficacy of Resmetirom, NITs and Regulatory Science

S4-E2 - NASH-TAG 2023, Part 2: Friday and Saturday Takeaways and AI-Assisted Histologic Assessment

S4-E1 - NASH-TAG 2023, Part 1: Expansion in NIT Knowledge and How NASH Drug Development is Changing Patient Advocacy Today

S3-E63.3 - Year-End Interview with Ian Rowe

S3-E63.2 - Year-End Interview with Stephen Harrison

S3-E63.1 - Year-End Interview with Naim Alkhouri

S3-E63 - 2022 NAFLD Year-in-Review Interview Series, Part 3

S3-E62.3 - Year-End Interview with Jeff Lazarus

S3-E62.2 - Year-End Interview with Ken Cusi

S3-E62.1 - Year-End Interview with Mazen Noureddin

S3-E62 - 2022 NAFLD Year-in-Review Interview Series, Part 2

S3-E60.5 - Madrigal Announcement on Resmetirom: Combination Therapy and Closing Takeaways

S3-E60.4 - Madrigal Announcement on Resmetirom: Basic Science and Impact on Future Use of NITs

S3-E60.3 - Madrigal Announcement on Resmetirom: Diving into Implications

S3-E60.2 - Madrigal Announcement on Resmetirom: First Reactions and Differing Perspectives

S3-E60.1 - Donna Cryer on the Far-Reaching Implications of Madrigal’s Emerging Story on Resmetirom

S3-E61 - NASH-TAG 2023 Preview with Stephen Harrison

S3-E60 - Madrigal Announces Breaking News: Positive Topline Results from Pivotal MAESTRO-NASH Trial of Resmetirom

S3-E59.3 - Year-End Interview with Donna Cryer

S3- E59.2 - Year-End Interview with Hannes Hagström

S3-E59.1 - Year-End Interview with Scott Friedman

S3-E59 - 2022 NAFLD Year-in-Review Interview Series, Part 1

S3-58.5 - From the Vault: Part 2: Jörn Schattenberg, Louise Campbell and Roger Green discuss NAFLD and SurfingNASH.com

S3-58.4 - From the Vault: Part 1: Jörn Schattenberg, Louise Campbell and Roger Green discuss NAFLD and SurfingNASH.com

S3-E58.3 - NAIL-NIT Retrospective Analysis and the Role of Consortia in Reshaping the Focus of NITs

S3-E58.2 - Expanding Benefits in FibroScan Use and Integrating Digital Tools

S3-E58.1 - Returning to In-Person Meetings and Emerging News on NICE and FibroScan

S3-E58 - Surfing 2022: NAFLD Year-in-Review

S3-E57.5 - From the Vault: “Seeing what Should Be” – Imaging the Liver To Assess Functioning Hepatocytes

S3-E57.4 - Discussing Critical Success Factors for Placebo Cohorts

S3-E57.3 - A Priori Placebo Response Rates and Challenges in Managing Samples Through Trials

S3-E57.2 - Origins of the Liver Forum and Capturing the Richness of Data Emerging from NASH Studies

S3-E57.1 - Veronica Miller on Traversing from the HIV Forum to the Liver Forum

S3-E57 - The Liver Forum: Fighting Fatty Liver Using Collective Knowledge and Experience

S3-E56.6 - From the Vault: Focus On NASH Cirrhosis: Trials in Process and a Plea For MRE

S3-E56.5 - Improving Patient Self-Management and Key Takeaways on Nutrition for NASH Resolution

S3-E56.4 - Integrated Solutions for Improved Patient Support

S3-E56.3 - The Psychology of Decision-Making Around Diet and Professional Support

S3-E56.2 - Setting and Driving Realistic Goals, and Dietician Visits as a Life-Long Therapy

S3-E56.1 - Weight Reduction for NASH Resolution: Strategies for Long-Term Adherence to Lifestyle Modifications

S3-E56 - Focus on the Intersection of Nutrition and NASH

S3-E55.6 - From the Vault: #NASHDay 2022 Wrap-Up Panel: The Importance of #StopNASHNow

S3-E55.5 - Pediatric and Lean NASH: Learning from Diverse Populations

S3-E55.4 - Emerging Roles for ELF Test and Advances in Use of PPARs

S3-E55.3 - NIT Efficacy in Primary Care and Diabetes Clinic Settings

S3-E55.2 - Comparing Global Health Systems, Standardizing AST and Educating on NAFLD Prevalence

S3-E55.1 - Insights from Fatty Liver Foundation’s Annual Survey of Patient Perspectives

S3-E55 - 2022 AASLD Wrap-Up: Reviewing a Momentous Meeting

S3-E54.4 - An Interview with Michael Cooreman, CMO of Inventiva

S3-E54.3 - Exploring Mitochondrial Uncouplers in NASH and a Reanalysis of REGENERATE Study's Phase 3 Results

S3-E54.2 - Presentation on Efruxifermin in NASH with Fibrosis

S3-E54.1 - Utilizing Best Practices in Diagnostics

S3-E53.3 - Pan-Society Presentation of NAFLD Nomenclature Consensus Process

S3-E53.2 - Serum Metabolomics, Gene Therapy and the Waning Future of Biopsy

S3-E53.1 - The Gut Microbiome and Complexities of NAFLD

S3-E54 - AASLD 2022 Liver Meeting Live Coverage: Part 2

S3-E53 - AASLD 2022 Liver Meeting Live Coverage: Part 1

S3-E52.6 - From the Vault: AASLD 2021: The Path To Making NITs the “Gold Standard” for Drug Trials

S3-E52.5 - 2022 AASLD Preview: Final Thoughts

S3-E52.4 - Exploring the NAFLD-Metabolic Link Through Screening Tools

S3-E52.3 - Remote Wellness Tools and Disease Management

S3-E52.2 - Efficacy of NITs and Predictive Outcomes

S3-E52.1 - FIB-4 and the Way Forward in Primary Care Screening

S3-E52 - Part 2: A Preview of the 2022 AASLD Liver Meeting

S3-E51.5 - From the Vault: AASLD 2021 Wrap-up

S3-E51.4 - Discussing the NAFLD-Cancer Link and Fatty Liver Awareness

S3-E51.3 - AASLD 2022: A Preview of Patient Advocate Coverage on Liver Health Equity

S3-E51.2 - Fibrosis Progression Rates for Diabetic vs. Non-Diabetic Patients

S3-E51.1 - Preview of MAESTRO-NASH Results: a 2,000-Patient Phase 3 Trial

S3-E51 - A Preview of the 2022 AASLD Liver Meeting

S3-E50.6 - From the Vault: Digital Health and Patient Empowerment: a Conversation with Dr. Marcus Ranney

S3-E50.5 - FIB-4 as a Front-Line Tool for Primary Care Triage

S3-E50.4 - Economics and Challenges of Pathway Design

S3-E50.3 - Patient Input for Clinical Care Pathways and Guidelines

S3-E50.2 - The Future of Digital Therapeutics and Patient Wellness Tools

S3-E50.1 - Patient Needs and Inputs for Trial Design

S3-E50 - Focus on Patient Advocacy

S3-E49.5 - From the Vault: The NICE Draft Guidance vs. The Economics of NAFLD: A Bad Fit

S3-E49.4 - Delivering Meaningful Liver Test Results to Patients

S3-E49.3 - Linking Liver Outcomes and Socioeconomic Status

S3-E49.2 - Cancer vs Liver Disease Management: Political Pressures and Metaphorical Issues

S3-E49.1 - NICE on FibroScan for Primary Care

S3-E49 - NICE and VCTE Use in Community Settings

S3-E48.6 - From the Vault: Themes From NASH-TAG 2022: Insights on Combination Therapies

S3-E48.5 - Phase 3 Results of the REVERSE Trial by Intercept

S3-E48.4 - Promising Interim Data from Axcella’s Phase 2B EMMPACT Study

S3-E48.3 - More Positive Phase 2B Results from Poxel

S3-E48.2 - Phase 2B 'Wow!' Results from Akero’s HARMONY Trial

S3-E48.1 - Results of Altimmune’s 12 week Phase 1B Study of Pemvidutide

S3-E48 - Review of Exciting Clinical Trial Press Releases

S3-E47.6 - From the Vault: Most important Story of Summer: Ian Rowe says “FDA ELF Approval”

S3-E47.5 - Combination NIT Biomarkers and Developing a Viable System for Treating Patients

S3-E47.4 - Potential Bottlenecks in Getting Drugs to NAFLD Patients

S3-E47.3 - Implications of Positive Drug Trials and Eventual Approvals on NAFLD Treatment

S3-E47.2 - The role of multiple biomarker tests in the diagnostic process

S3-E47.1 - Collaborative energies shifting the force around Fatty Liver

S3-E47 - What does the next year hold for the NAFLD-metabolic disease link?

S3-E46.6 - From the Vault: Can Weight Loss From GLP-1s or Double/Triple Agonists Emulate the Effects of Bariatric Surgery in SPLENDOR?

S3-E46.5 - Discussing NITs and Final Thoughts on NAFLD Summit

S3-E46.4 - Weight Change and Lifestyle Modification in Clinical Trials

S3 E46.3 - Discussing Clinical Trial Design at the NAFLD Summit

S3-E46.2 - NAFLD Summit in Context and Learning from Failed Trials

S3-E46.1 - Underreported Alcohol Use and Treating Comorbidities

S3-E46 - A Review of the 2022 NAFLD Summit from Dublin

S3-E45.5 - From the Vault: What Can NAIL-NIT Retrospective Analysis Tell Us About NASH?

S3-E45.4 - Paris Review: NITs, Metabolic Disease and Final Thoughts

S3-E45.3 - Paris Review: Session 5 on Clinical Trial Innovation

S3-E45.2 - Paris Review: Opening and Closing Sessions

S3 E45.1 - Paris Review: Regulator Response and "Dynamic Tension”

S3-E45 - A Review of Paris NASH 2022 with Jeff McIntyre

S3-E44.6 - From Inside the Vault: Connecting the Dots at Paris NASH 2021

S3-E44.5 - Roger Green and Jeff Lazarus Discuss on NAFLD Summit

S3-E44.4 - Roger Green and Jeff Lazarus discuss NAFLD Nomenclature Conference and COVID-19

S3-E44.3 - Anticipating the Aftermath: Previewing Outcomes of Paris NASH

S3-E44.2 - Highlights from Paris NASH and an Integrated Multi-Specialty Approach

S3-E44.1 - Paris NASH Meeting Preview: Program Highlights on Metabolics

S3-E44 - A Preview of Paris NASH and NAFLD Summit 2022

From the Vault: Future NASH Drug Development: More Diverse Trial Populations and More Study of Combination NASH Drugs

S3-E43.5 - The Future of Combination Agents in NASH Therapy

S3-E43.4 - Optimizing Combination Agents

S3-E43.3 - Science Partnerships and NASH Trials

S3-E43.2 - Finding the Right Combinations in NASH Therapy

S3-E43.1 - Combination Agents for Fibrotic Regression

S3-E43 - Combination Agents: a Cornerstone Of Future NASH Therapy?

S3-E42.5 - From the Vault: NASH Patient Care and the Value of Patient Education

S3-E42.4 - Allied Health and Patient Empowerment for NAFLD

S3-E42.3 - Allied Health and Patient Empowerment for NAFLD

S3-E42.2 - Allied Health and Patient Empowerment for NAFLD

S3-E42.1 - Allied Health and Patient Empowerment for NAFLD

S3-E42 — Allied Health and Patient Empowerment for NAFLD

S3-E41.6 - From the Vault: Why NASH Drug Trials Fail

S3-E41.5 - Improving NASH Clinical Trials By Reducing Screen Fail Rates

S3-E41.4 - Improving NASH Clinical Trials By Reducing Screen Fail Rates

S3-E41.3 - Improving NASH Clinical Trials By Reducing Screen Fail Rates

S3-E41.2 - Improving NASH Clinical Trials By Reducing Screen Fail Rates

S3-E41.1 - Improving NASH Clinical Trials By Reducing Screen Fail Rates

S3-E41- Improving NASH Clinical Trials By Reducing Screen Fail Rates

S3-E40.5 - From the Vault: Why Cirrhosis Matters In Clinical Trial Strategy

S3-E40.4 - Challenges of Alcohol Screening in Fatty Liver Disease

S3-E40.3 - Importance of Early Diagnosis in Lean NASH

S3-E40.2 - A Simple Diagnostic Algorithm for Lean NASH

S3-E40.1 - Best Practices in Lean NASH: How the Article Came About

S3-E40 - Best Practices in Lean NASH -- Authors Provide Back Story

S3-E39.5 - From The Vault: Early, Accurate Patient Information Matters

S3-E39.4 - Patient Follow-Up Challenges in Modeling NASH Diagnostics

S3-E39.3 - NASH challenges: Early Diagnosis and NASH Patient Management

S3-E39.2 - What An Early Decision Models Tells Us About Fibrosis & Metabolic Diseases

S3-E39.1 - Creating An Early Diagnosis NASH Decision Model

S3-E39 - Reviewing a Decision Model for Early NASH Diagnosis

S3-E38.8 - From the Vault: Discussing Patient empowerment at INCBCN 2022

S3-E38.7 - From the Vault: How Ballooned hepatocyte Reads Affect NASH Clinical Trials

S3-E38.6 - From the Vault: Patient-Focused Drug Development from Global Liver Institute

S3-E38.5 - From the Vault: NAIL-NIT tackles NAS Score Challenges

S3-E38.4 - From the Vault: NITs & Advancing NASH Therapy at AASLD 2021

S3-E38.3 - From the Vault: Learning About Stellate Cells and Fibrosis at Paris NASH

S3-E38.2 - From the Vault: Scott Friedman on Fibrosis and Precision Medicine

S3-E38.1 - From the Vault: Why NASH Drug Trials Fail

S3-E38 - SurfingNASH 2nd Anniversary: Buzzsprout, Download Barriers and More!

S3-E37.5 - The Need to Focus on NASH Cirrhosis Patients

S3-E37.4 - The "Pincer Movement" In Cirrhosis Technology: Patient Support vs High-End MedTech

S3-E37.3 - Where Is The Next Cirrhosis Breakthrough?

S3-E37.2 - Can Today's Medicines Cause Fibrosis Regression in Cirrhosis Patients?

S3-E37.1 - Cirrhosis Screening & Diagnostic Tests

S3-E37 - What Do We Know That Can Help NASH Cirrhosis Patients Today?

S3-E36.5 - REGENERATE Redux: Clearing The Finish Line?

S3-E36.4 - REGENERATE Redux: Other Obeticholic Acid (OCA) Questions

S3-E36.3 - REGENERATE Redux: Safety and Tolerability With Obeticholic Acid

S3-E36.2 - REGENERATE Redux: What OCA Efficacy Results Mean For Patients

S3-E36.1 - REGENERATE Redux: Obeticholic Acid (OCA) Efficacy

S3-E36 - REGENERATE Redux - Can OCA Succeed With New Data?

S3-E35.5 - Liver Science At #ILC2022: Mid-Range Impact of Advances

S3-E35.4 - Liver Science At #ILC2022: Commercial Benefits From the New Liver Science

S3-E35.3 - Liver Science At #ILC2022: Stellate Cells, Omics and Novel Receptor Targets

S3-E35.2 - Liver Science At #ILC2022: The Interplay of Stellate Cell Dynamics and Hepatic Fibrosis

S3-E35.1 - Liver Science at #ILC2022: Circadian Rhythm and Stellate Cells

S3-E35 - #ILC2022 Look Back: Liver Science and Fibrosis

S3-E32.3 - #ILC2022 Looking Back: NASH Is a Complex Disease

S3-E32.2 - #ILC2022 Looking Back: NAFLD and Quality-of-Life

S3-E32.1 - #ILC2022 Looking Back: Patient Motivation and Systems Incentives

S3-E34.4 - #ILC2022 looking back: Crystal Balling and The Semaglutide Trial

S3-E33.2 - #ILC2022 Looking Back: Patient Engagement 2 -- Patient Communication

S3-E33.1 - #ILC2022 Looking Back: Patient Engagement 1 -- Nurses and Touchy Topics

S3-E34.3 - #ILC2022 Looking Back: Early Pemvidutide Results and a Little More on FIB-4

S3-E34.2 - #ILC2022 Looking Back: Other Thoughts on Resmetirom Presentations

S3-E34.1 - #ILC2022 Looking Back: Resmetirom Late-Breaker and Cirrhosis Study

S3-E34 #ILC2022 Wrap-Up 1: NASH Drug Development Excitement!

S3-E33 - Day 4 of ILC2022: Friendly Debates About NITs, PLUS Discussing the Patient Advocate's Perspective

S3-E32 - Days 1-3 of ILC 2022: The Value of FIB-4 and In-Person Meetings

S3-E30.4 - Highlighting Intriguing #ILC2022 Abstracts: Potential Uses of FIB-4

S3-E30.3 - Highlighting Intriguing #ILC2022 Abstracts: More on NAFLD Quality of Life

S3-E30.2 - Highlighting Intriguing #ILC2022 Abstracts: Elastography and the Importance of NAFLD Quality-of-Life Metrics

S3-E30.1 - Highlighting Intriguing #ILC2022 Abstracts: Machine Learning Identified NASH Biomarkers and a Cost-Effectiveness Study

S3-E30 - Previewing #ILC2022: Focus on NITs and Patients

S3-E29.2 - #NASHDay 2022 Wrap-Up Panel: The Importance of #StopNASHNow

S3-E29.1 - #NASHDay 2022 Wrap-up Panel: What #NASHDay Means To Our Community In 2022 and Why It Matters

S3-E28.4 - #NASHDay 2022 Preview: SurfingNASH Predictions

S3-E28.3 - #NASHDay 2022 Preview: Exciting NASH Community Collaboration and How It Drives Us Forward

S3-E28.2 - #NASHDay 2022 Preview: What New Approaches To Clinical Trial Design Will Mean For Our Community

S3-E28.1 - #NASHDay 2022 Preview: New Approaches To Clinical Trial Design

S3-E29 - #NASHDay 2022: SurfingNASH Wrap-up

S3-E28 - Previewing #NASHDay 2022: Patient Advocacy Thrives!

S3-E27.6 - 5th Global NASH Congress Wrap-Up: Dual Weight Loss Agonists, Expanded Imaging and the Implications for NAFLD

S3-E27.5 - 5th Global NASH Congress Wrap-Up: NAFLD Screening in Primary Care Practices With The GRIP Program

S3-E27.4 - 5th Global NASH Congress Wrap-Up: An Interview with Becky Taub

S3-E27.3 - 5th Global NASH Congress Wrap-Up: Key NAFLD Topics In The Room

S3-E27.2 - 5th Global NASH Congress Wrap-Up: Quality-of-Life and Portable Liver Scans

S3-E27.1 - 5th Global NASH Congress Wrap-Up: Fatty Liver Science and Patient Advocacy

S3-E27 - 5th Global NASH Congress Wrap-Up: Highlights & Speaker Interviews

S3-E26.4 - Advancing NASH Best Practices In NITs: Answering Questions, Next Steps

S3-E26.3 - Advancing NASH Best Practices In NITs: Optimizing a NASH Biomarker Set

S3-E26.2 - Advancing NASH Best Practices In NITs: "Stacking" NASH Biomarkers

S3-E26.1 - Advancing NASH Best Practices In NITs: Quentin Anstee's Five Key Takeaways

S3-E26 - What Are We Learning About Clinical Trial Best Practices For NITs?

S3-E25.6 - Emerging Concepts In NASH: NAFLD Patient Screening, NASH Management

S3-E25.5 - Emerging Concepts in NASH: Fatty Liver Pathophysiology, Epidemiology, Co-Morbidities

S3-E25.4 - NASH Drug Development in 2022: Will Quality of Life Data Help NASH Drugs Over the Finish Line?

S3-E25.3 - Future NASH Drug Development: More Diverse Trial Populations and More Study of Combination NASH Drugs

S3-E25.2 - NASH Drug Development In 2022: A Wealth of Data and a Promising NASH Pipeline

S3-E25.1 - NASH Drug Development in 2022: Late-Stage NASH Drugs and Their Path to Market

S3-E25 - Crystal Ball Looks at Drug Development and the NASH Pipeline

S3-E24.5 - From #INCBCN: Digital Health and Patient Empowerment: a Conversation with Dr. Marcus Ranney

3-E24.4 - Innovations in NAFLD Care Conference: What Is the Importance of Steatosis in Metabolic Health?

S3-E24.3 - Stakeholder Diversity at the Innovations in NAFLD Care 2022 Conference: a Critical Success Factor

S3-E24.2 - Controversy at the Innovations in NAFLD Care Conference: What Does Patient Empowerment Mean in Fatty Liver Disease?

S3-E24.1 - Did the Innovations in NAFLD Care Conference Strengthen the Case for an Integrated NAFLD Care Pathway?

S3-E24 - #INCBCN (Innovations in NAFLD Care 2022) Wrap-up plus Interview with Human Edge Founder Dr. Marcus Ranney

S3-E23.5 - How NAFLD Patient Advocacy Works: Two Key Pieces

S3-E23.4 - How NAFLD Patient Advocacy Works: Targets and Opportunities for the Fatty Liver Community

S3-E23.3 - How NAFLD Patient Advocacy Works: Disease Targets and Policy Successes in The Fatty Liver Community

S3-E23.2 - How NAFLD Patient Advocacy Works: Targets and Opportunities for the Fatty Liver Community

S3-E23.1 - NAFLD Patient Advocacy: Meet the Advocates And Hear Their Stories

S3-E23 - So How Does NAFLD Patient Advocacy Support the Entire Fatty Liver Community?

S3-E22.4 - Previewing the 5th Global NASH Congress: Summing Up

S3-E22.3 - Previewing the 5th Global NASH Congress: NASH Drug Development Presentations

S3-E22.2 - Previewing the 5th Global NASH Congress: What can We Learn About Drugs in Development From Hepatic Cell Models and Advanced Omics?

S3-E22.1 - Previewing the 5th Global NASH Congress: Gut Microbiome and Nutrition are the New Frontier

S3-E22 - NASH Tsunami previews the 5th Global NASH Congress

S3-E21.5 - NAFLD Provider education, NASH Patient Care and Digital Health

S3-E21.4 - Donna Cryer Discusses NCQA on NASH Quality and the New GLI "Liver Health is Public Health" campaign

S3-E21.3 - Digital Health and Behavioral Support apps in Future NASH Therapies

S3-E21.2 - NAFLD Incidence in All Americans and The NASH-Diabetes Link

S3-E21.1 - Challenges in NAFLD Care Delivery: Primary Care and NASH

S3-E21 - Naim Alkhouri and Donna Cryer Bring News to Surfing the NASH Tsunami

S3-E20 - Jörn Schattenberg, Louise and Roger discuss NAFLD and SurfingNASH.com

S3-E19.5 - NAIL-NIT: Expanding Vistas for Phase 1 Research

S3-E19.4 - NAIL-NIT: "Morphic Resonance" and FDA Test Criteria

S3-E19.3 - NAIL-NIT: What Naim Alkhouri and Jörn Schattenberg Plan for Retrospective Analysis

S3 - E19.2 - Beginnings And Core Principles In The Move Beyond the Biopsy

S3-E19.1 - Podcast News: SurfingNASH.com Is Here and a New Role for Jörn Schattenberg!

3-E19 - What Can NAIL-NIT Retrospective Analysis Tell Us About NASH Clinical Trials?

S3-E18.4 - Previewing Innovations in NAFLD Care 2022: Day Two Sessions

S3-E18.3 - Previewing Innovations in NAFLD Care 2022: SItes of Care and Organizing Patients

S3-E18.2 - Previewing Innovations in NAFLD Care 2022: NASH Epidemiology

S3-E18.1 - Why the Innovations in NAFLD Care Conference Came to Be

S3-E18 - Previewing The Innovations In NAFLD Care 2022 Conference

S3-E17.4 - What Can Single Cell Genomics Teach about Hepatic Regeneration?

S3-E17.3 - Spatial Transcriptomics and The History of Single Cell Genomics

S3-E17.2 - Future Targeted NASH Therapies and NASH Drug Development Today

S3-E17.1 - Potential Breakthrough in Anti-Fibrotic Therapies Through mRNA/CAR-T Combined Therapies

S3-E17 - New In NASH Science: CAR-T/mRNA Anti-Fibrotics and Advanced NASH omics

S3-E16.5 - Ready for "Prime Time?" - MRE and Hepatogram in NASH Clinical Practice

S3-E16.4 - What a Disease Model Suggests about the NASH Diagnostic Path

S3-E16.3 - What a Disease Model tells Us About NASH Patient Management

S3-E16.2 - What a NASH Disease Model Reveals About Treating Advanced Fibrosis

S3-E16.1 - Building a Disease Model for NASH Prevalence: Key Challenges

S3-E16 - The Prospective Role of Data Modeling in Diagnostic and Drug Development

S3-E15.4 - CLDF Liver Connect program: How Well Did It Work?

S3-E15.3 - From the 2022 Liver Conference: Pediatric NAFLD and Liver Health Education

S3-E15.1 - An Interview with CLDF President Zobair Younossi about Liver Connect

S3-E15.2 - Discussing Health Disparities at CLDF's NASH Connect Conference

S3-E15 - Discussing NAFLD and NASH at CLDF's 2nd Annual Liver Connect

S3-E14.5 - Improving Ballooned Hepatocyte Analysis Through Artificial Intelligence

S3-E14.4 - Ballooned Hepatocyte Analysis and Reassessing Drug Development

S3-E14.3 - Systematic Flaws in Semi-Quantitative Ballooned Hepatocyte Analysis

S3-E14.2 - Can We Manage Statistical Error in Ballooned Hepatocyte Analysis Better?

S3-E14.1 - How Ballooned Hepatocyte Analytics Weaken NASH Clinical Trials

S3-E14 - NAS Scores and the Challenge of Complex Ballooned Hepatocytes

S3-E13.4 - The NICE Draft Guidance vs. The Economics of NAFLD: Not a Great Fit

S3-E13.3 - NICE Draft Guidance on NAFLD Screening: Long Term Issues

S3-E13.2 - NICE Assesses FibroScan Screening: Health Economics & NAFLD

S3-E13.1 - NICE Assesses FibroScan Community Screening: Analytic Tensions

S3-E13 - Community Screening for NAFLD: What Must Advocates Prove?

S3 E12.4 - What Will Improve NASH Care For Black Americans Most and Fastest

S3-E12.3 - The Need: Enrich Black America's NASH Clinical Trials Share

S3-E12.2 - Why NASH Might Be Different For Black Americans: SDOH, Omics

S3-E12.1 - NASH Care for Non-Hispanic Black Americans: The Issues and Why They Matter

S3-E12 - Non-Hispanic Black Americans, SDOH and NASH

S3-E11.4 - NAIL-NIT: Retrospective Analysis, Then Prospective Studies

S3-E11.3 - NAIL-NIT and the Challenges of the NAS Score

S3-E11.2 - NAIL-NIT and the Challenges of Histopathology

S3-E11.1 - NAIL-NIT: The Thinking Behind a New NAFLD Consortium

S3-E11 - NAIL-NIT and the Path from Non-Invasive Testing To Outcomes

S3-E10.4 - Value of Screening for NAFLD as NASH Prevalence Grows

S3-E10.3 - Value of Early NASH Diagnosis as NAFLD Prevalence Grows

S3-E10.2 - What Does the SUNN Study Say About NASH Prevalence?

S3-E10.1 - NAFLD and NASH Prevalence and Advanced Liver Fibrosis in Germany

S3-E10 - Screening and Treatment Pathways in a World with High NAFLD Prevalence

S3-E9.4 - NASH Patient Care: The Value of Patient Education

S3-E9.3 - NASH Patient Education: Liver Nurses' Roles

S3-E9.2 - NASH Patient Support: Liver Nursing Challenges

S3-E9.1 - NASH Patient Support: Meet Today's Liver Nurses

S3-E9 - Are We Taking Full Advantage of the Skills and Knowledge that Liver Nurses and Advanced Nurse Practitioners Bring To NASH Education and Patient Care?

S3-E8.4 - SurfingNASH Discusses The Innovations In NAFLD Care 2022 Series With Jeff Lazarus And Jörn Schattenberg: Agenda Concepts

S3-E8.3 - SurfingNASH Discusses The Innovations In NAFLD Care 2022 Series With Jeff Lazarus And Jörn Schattenberg: Structural Healthcare Issues

S3-E8.2 - SurfingNASH discusses the Innovations in NAFLD Care 2022 Series with Jeff Lazarus and Jörn Schattenberg: Program Scope and Key Elements

S3 E8.1 - SurfingNASH Discusses The Innovations In NAFLD Care 2022 Series With Jeff Lazarus And Jörn Schattenberg: Program Objectives

S3-E8 - The "Innovations in NAFLD Care 2022" Series: Promoting the NAFLD Public Health Agenda

S3-E6 - Themes From NASH-TAG 2022: Insights on Combination Therapies

S3-E5 - NASH-TAG 2022 bonus: A conversation with Donna Cryer and Scott Friedman

S3-E4.4 - NASH-TAG 2022 Wrap-up: Improving Cost Efficiency of NASH Trials By Reducing Screen Fail Rates

S3-E4.3 - NASH-TAG 2022 Wrap-up: NITs from The FDA and Patients' Perspectives

S3-E4.2 - NASH-TAG 2022 Wrap-up: The Fireside Chat and the Changing Paradigm For NASH Diagnostics

S3-E4.1 - NASH-TAG 2022 Wrap-up: High Impact presentations

S3-E4 - NASH-TAG 2022 Wrap-up: What Did We Learn about Fatty Liver Disease and Clinical Trial Design?

S3-E3 - NASH-TAG 2022 Day Two: Weight loss, Innovative Approaches and the Fireside Chat on Testing Methods

S3-E2 - NASH-TAG 2022 Day 1 Summary: NASH Combination Therapies, Artificial Intelligence, Basic Science

S3-E1 - Previewing NASH-TAG 2022: Are we Ready To Pivot On Testing Methods like Histopathology?

S2-E64.3 - SurfingNASH's 2021 NAFLD Year-In-Review Covers The Growing Energy and Impact of NASH Patient Advocacy

S2-E64.2 - SurfingNASH's 2021 NAFLD Year-in-Review Covers the Emerging NAFLD Public Health Agenda

S2-E64.1 - SurfingNASH's 2021 NAFLD Year-in-Review Explores Key NASH Themes of the Year Plus the Growth of Our Podcast

S2-E64 - Stephen Harrison, Jeff Lazarus and Andrew Scott Join SurfingNASH.com's 2021 NAFLD Year-in-Review

S2-E63.3 - SurfingNASH's 2021 NAFLD year-in-review Covers NASH Cost Effectiveness and Quality-of-Life

S2-E63.2 - SurfingNASH's 2021 NAFLD year-in-review Covers NASH Multidisciplinary Initiatives and the Clinical Care Pathways Paper

S2-E63.1 - SurfingNASH's 2021 NAFLD year-in-review Covers Cirrhosis Treatment Strategies Today and NASH Drugs in Development

S2-E63 - Manal Abdelmalek, Ken Cusi And Jörn Schattenberg Join SurfingNASH's 2021 NAFLD Year-In-Review

S2-E62.3 - SurfingNASH's 2021 NAFLD year-in-review Covers the Patient-Advocate Initiated and Sponsored SUNN Study

S2-E62.2 - SurfingNASH's 2021 NAFLD year-in-review Covers MRE and the Broader View of Non-Invasive Liver Testing

S2-E62.1 - SurfingNASH's 2021 NAFLD year-in-review Covers AI in Histopathology

S2-E62 - Mazen Noureddin, Alina Allen And Wayne Eskridge Join SurfingNASH's 2021 NAFLD Year-in-Review

S2-E61.4 - How Might the Role of Bariatric Surgery Change post-SPLENDOR?

S2-E61.3 - Can Weight Loss From GLP-1s or Double/Triple Agonists Emulate the Effects of Bariatric Surgery in SPLENDOR?

S2-E61.2 - What does SPLENDOR Tell Us About the Impact of Bariatric surgery on Cardiovascular and Liver Events?

S2-E61.1 - What does SPLENDOR Tell Us About MACE and MALO?

SPLENDOR Study Lead Author Discusses The Effect Of Bariatric Surgery On MACE And MALO

S2-E60.3 - Previewing NASH-TAG 2022 Sessions 7-9 - Focus On Non-invasive Testing and Novel Targets

S2-E60.2 - Previewing NASH-TAG 2022 Sessions 4-6 - Focus On the Major Consortia and Artificial Intelligence

S2-E60.1 - Previewing NASH-TAG 2022 Sessions 1-3 -- Focus on Drug Development

S2-E60 - Explore Major Upcoming Events and Issues for NAFLD and NASH At Our NASH-TAG 2022 Preview

S2-E59.4 - What Can We Do To Reshape a Potentially Disasatrous Growth in Cirrhosis?

S2-E59.3 - What's next in Driving the Global Health Agenda for NAFLD?

S2-E59.2 - Key Issues For the NAFLD Global Health Agenda: Prevalence and Cost Data

S2-E59.1 - How the global Health Agenda for NAFLD Was Developed

S2-E59 - Discuss the Global NAFLD Agenda publication With Lead Author Jeffrey Lazarus

S2-E58.3 - Focus On NASH Cirrhosis: Trials in Process and a Plea For MRE

S2-E58.2 - Focus On NASH Cirrhosis: Reviewing FALCON 2 and the Belapectin Post Hoc Analysis of Phase 2 Data

S2-E58.1 - Focus On NASH Cirrhosis: Why Cirrhosis Matters and Review of REVERSE Results at AASLD

S2-E57.4 - TLMdX 2021 From AASLD: What Does the Future Hold For NAFLD and NASH?

S2-E57.3 - 2021 TLMdX From AASLD: Non-conventional efficacy Metrics, Genomics of NAFLD and an Exciting Future

S2-E57.2 - 2021 TLMdX From AASLD: The Path To Making NITs the "Gold Standard" for Drug Trials

S2-E57.1 - 2021 TLMdX from AASLD: Putting a "Big, Fat Dent" in NAFLD and NASH

S2-E57 - AASLD 2021 Wrap-up: Looking Back on an Eventful TLMdX

S2-E56 - Day Four at the 2021 TLMdX From AASLD

S2-E55 - Day Three at the 2021 TLMdX From AASLD

S2-E54.3 - Inside the Patient-Focused Drug Development Meeting: the Advocates' Priorities

S2-E54.2 - Inside the Patient-Focused Drug Development Meeting: the Advocates' Perspectives

S2-E54.1 - Inside the Patient-Focused Drug Development meeting: Stories of Personal Experiences

S2-E58 - What's New In Clinical Trials for NASH Cirrhosis

S2-E54 - Go Inside a Pivotal Event: the NASH Patient-Focused Drug Development Meeting

S2-E53.3 - AASLD 2021 Preview: NASH Patient Management Topics Range From Drugs In Development To Applied Day-to-Day Issues

S2-E57.1 - 2021 TLMdX from AASLD: Putting a "Big, Fat Dent" in NAFLD and NASH

S2-E53.2 - AASLD 2021 Preview: A Weekend of Broad NASH Disease/Drug Management Coverage

S2-E53.1 - AASLD 2021 Preview: Presentations on Basic NASH Science

S2-E53 - SurfingNASH Previews AASLD 2021: the Digital Liver Meeting

S2-E52.4 - MRE Findings Suggest Flaws in Fibrosis As Endpoint

S2-E52.3 - Can MRE Provide Reliable, Non-Invasive Clinical Trial Endpoints?

S2-E52.2 - How Liver Stiffness Measures Can Improve Practical Patient Management

S2-E52.1 - MRE Predicts Long-Term Progression and Outcomes in Chronic Liver Disease Patients

S2-E52 - Predicting Long-Term Outcomes Using MR Elastography

S2-E51.3 - More from Paris NASH: Overcoming Histopathology's flaws

S2-E51.2 - More from Paris NASH: Precision Medicine's role in Drug Development and Patient Diagnosis

S2-E51.1 - More from Paris NASH: precision Medicine, Stellate Cells and Hepatic Influencers

S2-E51 - Precision medicine, Fibrosis, Liver Function and the Future: a Discussion With Scott Friedman

S2-E50.3 - "Dare to Dream" - How New Imaging Methods Can Change Our Future

S2-E50.2 - "Seeing What Should Be" - Imaging the Liver To Assess Functioning Hepatocytes

S2-E50.1 - "Potential Game Changer" - Imaging Can Provide a Dynamic View of NASH Evolution

S2-E50 - "Dare to Dream" - the Exciting, Evolving World of Organ Imaging

S2-E49.3 - Clinical Care Pathway: What Can Be Done Today?

S2-E49.2 - Clinical Care Pathway: Behavior Change and Prevalence Data

S2-E49.1 - Clinical Care Pathway: How It Came To Be

S2-E49 - Finally, a Clinical Care Pathway For a Hidden Pandemic!

S2-E48.4 - Closing Thoughts On Summer: What Mattered Most?

S2-E48.3 - Closing thoughts on Summer: Looking From a Patient-Based Perspective

S2-E48.2 - Closing Thoughts On Summer: More on FGF-21s and A Topical "Hijacking"

S2-E48.1 - Closing Thoughts On Summer: Mazen Noureddin's Two Big Things

S2-E48 - Closing Thoughts On an Eventful NASH Summer

S2-E47.3 - Most Important Story of Summer? Manal Abdelmalek Says, "NIH Funding Liver Cirrhosis Network"

S2-E47.2 - Most Important Story of Summer? Michelle Long Says, "Harrison/Alkhouri Prevalence Paper."

S2-E47.1 - Most important Story of Summer? Ian Rowe says, "FDA ELF Approval."

S2-E47 - Ask Opinion Leaders: The Biggest NAFLD/NASH Stories of Summer

S2-E46.3 - Top Stories From Paris NASH: Connecting the Dots

S2-E46.2 - Top Stories From Paris NASH: Deep Dive into Fibrosis

S2-E46.1 - Top stories from Paris NASH: Epidemiology and Clinical Aspects

S2-E46 - Highlights from Paris NASH

S2-E45.3 - Discussing the EASL Guidelines and the Path to A Non-Invasive Testing Future with Donna Cryer

S2-E45.2 - Discussing Non-Invasive Testing and the Patient Experience with Wayne Eskridge.

S2-E45.1 - Discussing Fatty Liver Disease Prevalence And Patient Awareness With Anthony Villiotti

S2-E45 - Ask the Advocates: The Biggest NAFLD/NASH Story of the Summer

S2-E44.4 - COVID-19 and Fatty Liver - What Impact Will the Delta Variant Have On Clinical Trials?

S2-E44.3 - COVID-19 And Fatty Liver - Areas for Confusion and Policy Discord

S2-E44.2 - COVID-19 And Fatty Liver - Lessons from Immunocompromised Patients and Other Countries

S2-E44.1 - COVID-19 And Fatty Liver --How Immunocompromised and Transplant Patients Became A Priority for Booster Doses

S2-E44 - The impact Of the COVID-19 Delta Variant on NAFLD and NASH

S2-E43.4 -Rethinking Cirrhosis: A Call To Action

S2-E43.3 - Driving A Reconsideration Of Cirrhosis In Drug Development

S2-E43.2 - Rethinking Cirrhosis As A Target For Drug Development

S2-E43.1 - Cirrhosis - Challenges in Treating Patients

S2-E43 - Can Cirrhosis Drive Drug Development In NASH?

S2-E42.3 - Why FGFs Matter - Episode Opening and Closing, Plus a Question About Screen Fail Rates

S2-E42.2 - How FGFs Work In The Body And What This Means For NAFLD And NASH

S2-E42.1 - FGF drugs in Development - A Promising Class of Agents

S2-E42 - How Do Fibroblast Growth Factor (FGF) Drugs Work and Why Are They So Important?

S2-E41.4 - Reasons To Believe That a Multidisciplinary Fight Against NASH Will Bring Value

S2-E41.3 - Critical Success Factors In the Multidisciplinary Fight Against NASH

S2-E41.2 - Specialties and Organizations Unite to Fight the NASH Epidemic

S2-E41.1 - SPECIAL FEATURE: Interview with Louise Campbell

S2-E41 - Preparing for the NASH Epidemic: Behind a Multidisciplinary Call to Action

S2-E40.3 - Discussing Comprehensive Care Models For NAFLD - Metrics, Key Performance Indicators and Improving Management

S2-E40.2 - Discussing Comprehensive Care Models For NAFLD - Providers Respond

S2-E40.1 - Discussing Comprehensive Care Models for NAFLD - Jeff Lazarus Presents Research

S2-E40 - Discussing Comprehensive Care Models for NAFLD

S2-E39.3 - 20K Celebration Interview With Jörn Schattenberg and Ian Rowe

S2-E39.2 - 20K Celebration Interviews With Stephen Harrison and Naim Alkhouri

S2-E39.1 - 20K celebration Interview with Donna Cryer

S2-E39 - Celebrating Two Milestones for SurfingNASH!

S2-E38.3 - Creating an Ecosystem of Community Physicians To Support Clinical Trials

S2-E38.2 - Building a Culture That Encourages Patient Participation

S2-E38.1 - Motivating Underserved Patients to Participate in Clinical Trials

S2-E38 - Increasing Diversity in the Clinical Trial Patient Population

S2-E37.3 - Spreading the NASH Message Throughout the Broader Community Of Healthcare Practitioners

S2-E37.2 - NASH Diagnostics Provide a Natural Brake on Overly Broad Adoption of NASH Drugs

S2-E37.1 - Key Reasons the NASH Drug Market Will Evolve Differently From Statins

S2-E37 - Why the NASH Market Is Different From Statins

S2-E36.3 - From the #ILC2021 Wrap-up: Focus on Care Pathways and Treatment Roles

S2-E36.2 - From The #ILC2021 Wrap-Up: Focus On Drug Development

S2-E36.1 - From the #ILC2021 Wrap-up: Focus on Diagnostics

S2-E36 - #ILC2021 Wrap-Up: Big Issues, Key Takeaways, Remaining Issues

S2-E35 - #ILC2021 Day Four - Promising Times Ahead, Maybe With a Few More Bumps In the Road

S2-E34 - #ILC2021 Day Three - Multi-Disciplinary NAFLD Thinking, with Exciting Drugs on the Horizon

S2-E33 - #ILC2021 Day Two -- Learning About Patients Through Large Databases

S2-E32 - Leaders Provide Perspectives on #ILC2021

S2-E31.3 - Previewing Digital ILC 2021 -- Part II -- NITs, late-breakers and intriguing topics

S2-E31.2 - Previewing Digital ILC 2021 -- Part II -- Drug Development

S2-E31.1 - Previewing Digital ILC 2021 -- Part II -- "Favorite Things" and Discussing Metabolic issues

S2-E31 - DIgital ILC 2021 -- Preview II

S2-E30.3 - The Global Liver institute US NASH Action Plan - treatment and health system challenges

S2-E30.2 - The Global Liver Institute US NASH Action Plan - Common, Reliable Diagnostics Are Critical

S2-E30.1 - The Global Liver Institute US NASH Action Plan - Overview And What Education Must Achieve

S2-E30 - The Global Liver institute US NASH Action Plan - What It Is and How We All Can Help Support it

S2-E29.3 - Previewing Digital ILC 2021 -- Part 1 -- What might emerge?

S2-E29.2 - Previewing Digital ILC 2021 -- Part 1 -- Interests and Issues

S2-E29.1 - Previewing Digital ILC 2021 -- Part 1 -- Meeting Overview

S2-E29 - Previewing Digital ILC 2021 -- Part 1

S2-E27.2 - A Deeper Look At International NASH Day 2021 -- Activities, Future Plans, And Global Liver Institute Growth

S2-E27.1 - previewing International nASH day 2021 -- overview of events

S2 - E28 - SPECIAL EPISODE: What Can We Learn The Aldafermin Discontinuation In F2/F3 NASH?

S2-E27 - Previewing International NASH Day -- a growing Day of Global Education and Organizing

S2-E26.3 - How much will real-life NASH treatment decisions depend on the specialty of the prescriber?

S2-E26.2 - How simply "Vertebrate" will future NASH therapy be?

S2-E26.1 - What will NASH Pharmacotherapy Look Like When we have Multiple Options?

S2-E26 - What Will Treatment Pathways Look Like For NASH Patients?

S2-E25.3 (CORRECTED) - Prevalence of NAFLD and NASH 2021 -- An Urgent Call to Action

S2-E25.2 (CORRECTED) - Prevalence of NAFLD and NASH 2021 -- Deeper Dive

S2-E25.1 (CORRECTED) - Prevalence of NAFLD and NASH 2021 -- Key Findings

S2-E25 - How many Americans Are Living with NAFLD and NASH?

S2-E24.3 - From The Fourth Global NASH Congress -- How Diagnostics Will Evolve Over The Next Several Years

S2-E24.2 - From The Fourth Global NASH Congress -- How Treatment WIll Evolve Over The Next Several Years

S2-E24.1 - From the Fourth Global NASH Congress -- Changing Paradigms and Guidelines

S2-E24 - Fourth Global NASH Congress -- Wrapping Up

S2-E23.1 - From the Fourth Global NASH Congress -- Diagnosing Diagnostics

S2-E23 - Wrapping up Day Two of the Fourth Global NASH Congress -- Drugs, lifestyles and Health policy

S2-E22 - Day Two at the 4th Global NASH Congress -- many New Drugs and Non-Pharmacologic Interventions

S2-E21 - Day One At The 4th Global NASH Congress -- Diagnostics, Drugs And Regulatory Issues

S2-E20.3 - How Can we Best Use NASHmap in Clinical trials and Patient Treatment?

S2-E20.2 - What Can We Learn about NASH From NASHmap?

S2-E20 - 14-variable Machine Learning model identifies Probable NASH patients from Electronic Health Records

S2-E20.1 - How NASHmap, the 1st Machine Learning Model to Identify Probable NASH Patients, Came to Life

S2-E19.3 - Pharmacotherapy Themes At The 4th Global NASH Congress

S2-E19.2 - Patient-Centric Themes At The 4th Global NASH Congress

S2-E19.1 - Non-Invasive Testing Themes at the 4th Global NASH Congress

S2-E19 - Previewing the 4th Global NASH congress

S2 E18.3 -- Stephen Harrison and Alina Allen discuss what her work portends for future trials.

S2 E18.2 -- How Might We Treat Differently If We Knew Which Cirrhotic Patients Are Likely To Progress?

S2 E18.1 -- How Does MR Elastography Help Identify NASH PAtients Who Are Likely To Progress?

S2-E18 - Magnetic Resonance Elastography Predicts Prognosis for NASH patients

S2-E17.3 -- The value of ultrasound and the goals of patient screenin

S2-E17.2 — Modeling the relative impact of treating NASH vs. CVD in patients with different fibrosis levels

S2-E17.1 - Questions in Screening: Do Liquid Tests Bring Better Value than Elastography?

S2-E17 - New lessons from Leeds: Streamlining Non-Invasive Testing algorithms

S2-E16.3 - How NASH treatment Might Evolve as Therapies Come to Market

S2-E16.2 - Future Directions for NASH Cost-Effectiveness Research

S2 E16.1 -- How Cost-Effectiveness Research On Widespread NIT Screening In The U.S. Has Evolved

S2-E16 -- Cost-Effectiveness of Widespread Non-Invasive NASH Testing and Treatment

S2-E15 — Wrapping Up NASH-TAG 2021

S2-E14 - NASH-TAG Session 4 Summary: Basic Science and Promising Drugs on the Horizon

S2-E13 - NASH-TAG Session 3 Summary: Trial Designs of the Future and the Future of Diabetes Drugs in NASH

S2-E12 - NASH-TAG Session 2 Summary: Innovative Trial Design and Robust Histologic Analyses

S2 E11 — NASH-TAG Session 1 summary: Major Drugs in Development and Why Trials Fail

S2 E10 — Before NASH-TAG, Conversations With Co-Directors

S2-E9.2—Drug-Free Treatment of Early Fatty Liver Disease: Issues for Public Health

S2-E9.3 — Introducing LIVErHEALTHY: a program for patients with Early Fatty Liver disease

S2-E9.1—Drug-Free Treatment of Early Fatty Liver Disease: Identity matters

S2-E9 - Novel Approaches to Drug-Free Treatment of Early Fatty Liver Disease

S2-E8.3 - Previewing NASH-TAG 2021: Two intriguing side conversations

S2-E8.2 - Previewing NASH-TAG 2021: Day Two

S2-E8.1 - Previewing NASH-TAG 2021: Day One

S2-E8 - Previewing NASH-TAG 2021

S2-E7.3 - The newer diabetes drugs and NASH: Educating and Motivating Stakeholders

S2-E7.2 - The Newer Diabetes Drugs and NASH: How T2D Patients are likely to respond

S2-E7.1 - The Newer Diabetes Drugs and NASH: Modes of Action

S2-E7 - The Newer Diabetes Drugs and Patients with NASH

S2 E6.3 - #RealTalk: Trial Recruiting Challenges: Traps to Avoid in designing patient protocols for NASH Trials